





























# Danske Markets has a leading equity capital markets franchise

## Equity Capital Markets (Denmark)

<p>DKK 983 million</p>  <p><b>jeudan</b></p> <p>Rights issue of Jeudan shares <i>Lead Manager</i></p>	<p>DKK 101 million</p> <p><b>FØROYABANKI</b></p> <p>Placing of Føroya Banki shares <i>Sole Bookrunner</i></p>	<p>DKK 483 million</p> <p><b>ROCKWOOL®</b></p> <p>Accelerated bookbuild of Rockwool International B shares <i>Sole Bookrunner</i></p>	<p>DKK 660 million</p>  <p>Accelerated bookbuild of Coloplast B shares <i>Sole Bookrunner</i></p>	<p>DKK 419 million</p>  <p>Rights issue of Royal Unibrew shares <i>Joint Lead Manager</i></p>	<p>DKK 429 million</p> <p><b>NEUROSEARCH</b></p> <p>Rights issue of NeuroSearch shares <i>Global Coordinator</i></p>
<p>DKK 200 million</p>  <p><b>jeudan</b></p> <p>Directed issue of Jeudan shares <i>Sole Lead Manager</i></p>	<p>DKK 38 million</p> <p><b>BoConcept</b></p> <p>Accelerated bookbuild of BoConcept Holding B shares <i>Sole Bookrunner</i></p>	<p>DKK 877 million</p> <p><b>Sydbank</b></p> <p>Accelerated bookbuild of primary shares <i>Joint Bookrunner</i></p>	<p>DKK 8.3 billion</p>  <p><b>MAERSK</b></p> <p>Accelerated bookbuild of treasury shares <i>Financial Adviser</i></p>	<p>DKK 1.4 billion</p> <p><b>DSV</b></p> <p>Accelerated bookbuild of DSV shares <i>Joint Bookrunner</i></p>	<p>DKK 459 million</p> <p><b>B&amp;O</b></p> <p><b>BANG &amp; OLUFSEN</b></p> <p>Rights issue of Bang &amp; Olufsen shares <i>Sole Lead Manager</i></p>
<p>DKK 274 million</p>  <p>Rights issue of Brdr. Hartmann shares <i>Joint Lead Manager</i></p>	<p>DKK 30.5 billion</p>  <p>Rights issue of Carlsberg shares <i>Global Coordinator</i></p>	<p>DKK 15.7 billion</p>  <p>Accelerated bookbuild of Carlsberg shares <i>Joint Bookrunner</i></p>	<p>DKK 409 million</p>  <p>Rights issue of LifeCycle Pharma shares <i>Joint Bookrunner</i></p>	<p>DKK 91 million</p> <p><b>Pharmexa</b></p> <p>Rights issue of Pharmexa shares <i>Sole Bookrunner</i></p>	<p>DKK 6.0 billion</p>  <p>Buyback of Lundbeck shares <i>Joint Bookrunner</i></p>

# Danske Markets has a leading equity capital markets franchise

## Equity Capital Markets (Denmark)

<p>DKK 135 million</p>  <p>IPO of Erria <i>Sole Bookrunner</i></p>	<p>DKK 500 million</p>  <p>Buyback of EAC shares <i>Sole Lead Manager</i></p>	<p>DKK 400 million</p>  <p>Buyback of DSV shares <i>Sole Lead Manager</i></p>	<p>DKK 771 million</p>  <p>Rights issue of NeuroSearch shares <i>Global Coordinator</i></p>	<p>DKK 635 million</p>  <p>Rights issue of Jeudan shares <i>Sole Lead Manager</i></p>	<p>DKK 340 million</p>  <p>Offering of primary Curalogic shares <i>Sole Bookrunner</i></p>
<p>DKK 360 million</p>  <p>Offering of primary TopoTarget shares <i>Joint Bookrunner</i></p>	<p>DKK 400 million</p>  <p>IPO of Exiqon <i>Sole Bookrunner</i></p>	<p>DKK 1.0 billion</p>  <p>Buyback of Codan shares <i>Sole Lead Manager</i></p>	<p>DKK 64 million</p>  <p>Private placement of new Pharmexa shares <i>Joint Bookrunner</i></p>	<p>DKK 14.7 billion</p>  <p>Accelerated bookbuild of primary Danske Bank shares <i>Joint Bookrunner</i></p>	<p>DKK 557 million</p>  <p>IPO of LifeCycle Pharma <i>Joint Bookrunner</i></p>
<p>DKK 397 million</p>  <p>Rights issue of NeuroSearch shares <i>Global Coordinator</i></p>	<p>-</p>  <p>IPO of Rella Holding (Holds 56.8% of Carl Allers Etablissement) <i>Sole Lead Manager</i></p>	<p>DKK 216 million</p>  <p>IPO of Curalogic <i>Sole Bookrunner</i></p>	<p>USD 28 million</p>  <p>Private placement of primary Egalet shares <i>Financial Adviser</i></p>	<p>DKK 6.3 billion</p>  <p>IPO of TrygVesta <i>Co-Lead Manager</i></p>	<p>DKK 259 million</p>  <p>IPO of TopoTarget <i>Joint Bookrunner</i></p>

















# Danske Markets has a leading equity capital markets franchise

## Equity Capital Markets (Finland)

<p>EUR 78 million</p>  <p>Rights issue of HKScan shares <i>Lead Manager</i></p>	<p>EUR 208 million</p>  <p>Rights issue of Sponda shares <i>Global Coordinator</i></p>	<p>EUR 40 million</p>  <p>Directed share issue of Kuntarahoitus shares <i>Lead Manager</i></p>	<p>EUR 120 million</p>  <p>Accelerated bookbuilding of Finnair shares <i>Sole Bookrunner</i></p>	<p>EUR 248 million</p>  <p>Rights issue of Finnair shares <i>Global Coordinator</i></p>	<p>EUR 17 million</p>  <p>Directed issue of new Eckerö shares <i>Lead Manager</i></p>
<p>EUR 2.0 billion</p>  <p>IPO and spin-off of Oriola-KD from Orion <i>Sole Lead Manager</i></p>	<p>EUR 60 million</p>  <p>IPO of Salcomp <i>Lead Manager</i></p>	<p>Amount undisclosed</p>  <p>Listing of Amanda shares on the Helsinki Stock Exchange <i>Financial Adviser</i></p>	<p>EUR 7 million</p>  <p>Private placement of BasWare shares <i>Lead Manager</i></p>	<p>EUR 10 million</p>  <p>Rights issue of BioTie Therapies shares <i>Lead Manager</i></p>	<p>Amount undisclosed</p>  <p>Listing of Belton on Helsinki Stock Exchange's main list <i>Financial Adviser</i></p>
<p>EUR 32 million</p>  <p>Private placement of Teknoinvest shares <i>Lead Manager</i></p>	<p>EUR 1.0 billion</p>  <p>Rights issue of Sonera shares <i>Lead Manager</i></p>	<p>EUR 128 million</p>  <p>Reversed IPO of CapMan <i>Financial Adviser</i></p>	<p>EUR 8 million</p>  <p>Private placement of Central Pharma shares <i>Financial Adviser</i></p>	<p>EUR 42 million</p>  <p>IPO of SSH Communications Security <i>Global Coordinator</i></p>	<p>EUR 47 million</p>  <p>Private placement of Elcoteq shares <i>Lead Manager</i></p>














# Danske Markets has a leading equity capital markets franchise

## Equity Capital Markets (Norway)

<p>Pending</p>  <p>IPO of Wilh. Wilhelmsen ASA (Split of company) <i>Joint Lead Manager</i></p>	<p>NOK 19.3 billion</p> <p><b>StatoilHydro</b></p> <p>Acquisition of 4.5% of StatoilHydro by the Norwegian Ministry of Petroleum and Energy <i>Approved Purchaser</i></p>	<p>NOK 45 million</p>  <p>Private placement of Phonect shares <i>Financial Adviser</i></p>	<p>USD 300 million</p>  <p>IPO of Bergesen Worldwide Offshore <i>Joint Bookrunner</i></p>	<p>NOK 321 million</p>  <p>Private placement to API Eiendomsfond <i>Joint Lead Manager</i></p>	<p>NOK 28 million</p>  <p>Private placement of Nacre shares <i>Financial Adviser</i></p>
<p>NOK 46 million</p>  <p>Private placement of Vensafe shares <i>Sole Lead Manager</i></p>	<p>NOK 147 million</p>  <p>Private placement of VMETRO shares <i>Joint Lead Manager</i></p>	<p>NOK 700 million</p>  <p>Private placement of Fjord Seafood shares <i>Lead Manager</i></p>	<p>NOK 100 million</p>  <p>Private placement of Fjord Marin shares <i>Lead Manager</i></p>	<p>NOK 142 million</p>  <p>Private placement of TGS Nopec shares <i>Lead Manager</i></p>	<p>NOK 30 million</p> <p><b>AKVA</b>GROUP</p> <p>Rights issue of AKVA smart shares <i>Lead Manager</i></p>
<p>NOK 270 million</p>  <p>Private placement of VMETRO shares <i>Joint Lead Manager</i></p>	<p>NOK 90 million</p>  <p>Offering of MediCult shares <i>Joint Lead Manager</i></p>	<p>NOK 728 million</p>  <p>IPO of Fjord Seafood <i>Lead Manager</i></p>	<p>NOK 83 million</p>  <p>Private placement of Nordic VLSI shares <i>Lead Manager</i></p>	<p>NOK 203 million</p>  <p>Rights issue of Otrum shares <i>Lead Manager</i></p>	<p>NOK 80 million</p>  <p>Offering of VMETRO shares <i>Lead Manager</i></p>

# Danske Markets has a leading equity capital markets franchise

## Equity Capital Markets (Sweden)

<p>SEK 253 million</p>  <p>Rights issue of Cision shares <i>Joint Lead Manager</i></p>	<p>SEK 5.0 billion</p>  <p>Rights issue of SAS shares <i>Co-Lead Manager</i></p>	<p>SEK 978 million</p>  <p>Rights issue of Billerud shares <i>Joint Lead Manager</i></p>	<p>SEK 2.5 billion</p>  <p>Rights issue of Eniro shares <i>Joint Lead Manager</i></p>	<p>SEK 100 million</p>  <p>Rights issue of Cybercom shares <i>Sole Adviser</i></p>	<p>SEK 44 million</p>  <p>Accelerated bookbuild of BioGaia B shares <i>Sole Bookrunner</i></p>
<p>SEK 6.1 billion</p>  <p>Rights issue of SAS shares <i>Co-Lead Manager</i></p>	<p>SEK 1.5 billion</p>  <p>Rights issue of Meda shares <i>Sole Lead Manager</i></p>	<p>SEK 73 million</p>  <p>Rights issue of Opcon shares <i>Sole Lead Manager</i></p>	<p>SEK 1,514 million</p>  <p>Rights issue of Getinge shares <i>Sole Lead Manager</i></p>	<p>SEK 80 million</p>  <p>Buyback of PEAB shares <i>Sole Lead Manager</i></p>	<p>SEK 23 million</p>  <p>Buyback of Peab Industri shares <i>Sole Lead Manager</i></p>
 <p>Listing on OMX Nordic Exchange <i>Financial Adviser</i></p>	<p>SEK 184 million</p>  <p>Buyback of SAAB Technologies shares <i>Lead Manager</i></p>	<p>SEK 85 million</p>  <p>Rights issue of Precise Biometrics shares <i>Sole Lead Manager</i></p>	<p>SEK 300 million</p>  <p>Private placement of Din Bostad shares <i>Co-Lead Manager</i></p>	<p>Amount undisclosed</p>  <p>Placement of primary and secondary shares in HTC to 3i <i>Financial Adviser</i></p>	<p>SEK 63 million</p>  <p>Private placement of primary Precise Biometrics shares <i>Joint Bookrunner</i></p>